Incyte (INCY) Stock Forecast & Price Target

Incyte is positioned to benefit from a resilient franchise anchored by Jakafi, which still offers growth in myelofibrosis, polycythemia vera, and graft-versus-host disease, while Opzelura adds a meaningful dermatology growth vector that could approach $0.9B in sales. The company’s appeal is strengthened by a broad oncology and inflammation pipeline, plus multiple partnered assets that generate low-risk cash flows and strategic optionality, including milestone, PRV, and royalty economics from Atebrioz without requiring a new commercial buildout. Near term, the $25M payment and expected roughly $205–225M of gross economics from Atebrioz, alongside internally developed KRAS G12D upside and a leverageable commercial infrastructure, support the positive fundamental outlook.

Incyte is facing a weak fundamental setup because its valuation still depends heavily on Jakafi, which faces patent expiry in the 2028 timeframe, pricing pressure, and slower-than-expected Jakafi XR conversion, while life-cycle extension efforts remain uncertain. Its oncology and dermatology pipeline adds optionality, but the company operates in highly competitive spaces where it is behind larger peers, and earlier-stage assets as well as niche indications may limit the size of future market share gains. A DCF using a 9% discount rate and 2% terminal growth rate implies roughly $29B to $30B in enterprise value, yet that support is vulnerable to weaker ‘989 results, disappointing ESMO oncology updates, and softer Opzelura demand after separating CMS benefits.